JP7792730B2 - 尿酸を降下させるために使用できる化合物 - Google Patents

尿酸を降下させるために使用できる化合物

Info

Publication number
JP7792730B2
JP7792730B2 JP2024563656A JP2024563656A JP7792730B2 JP 7792730 B2 JP7792730 B2 JP 7792730B2 JP 2024563656 A JP2024563656 A JP 2024563656A JP 2024563656 A JP2024563656 A JP 2024563656A JP 7792730 B2 JP7792730 B2 JP 7792730B2
Authority
JP
Japan
Prior art keywords
group
compound
substituted
cyano
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024563656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025514336A5 (enExample
JP2025514336A (ja
Inventor
史▲東▼方
傅▲長▼金
▲楊▼▲艶▼
李海明
袁承▲詣▼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atom Therapeutics Co Ltd
Original Assignee
Atom Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atom Therapeutics Co Ltd filed Critical Atom Therapeutics Co Ltd
Publication of JP2025514336A publication Critical patent/JP2025514336A/ja
Publication of JP2025514336A5 publication Critical patent/JP2025514336A5/ja
Application granted granted Critical
Publication of JP7792730B2 publication Critical patent/JP7792730B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024563656A 2022-04-27 2023-04-27 尿酸を降下させるために使用できる化合物 Active JP7792730B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210456939 2022-04-27
CN202210456939.3 2022-04-27
PCT/CN2023/091140 WO2023208108A1 (zh) 2022-04-27 2023-04-27 可用于降尿酸的化合物

Publications (3)

Publication Number Publication Date
JP2025514336A JP2025514336A (ja) 2025-05-02
JP2025514336A5 JP2025514336A5 (enExample) 2025-10-08
JP7792730B2 true JP7792730B2 (ja) 2025-12-26

Family

ID=87872273

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563656A Active JP7792730B2 (ja) 2022-04-27 2023-04-27 尿酸を降下させるために使用できる化合物

Country Status (6)

Country Link
US (1) US20250282753A1 (enExample)
EP (1) EP4516781A4 (enExample)
JP (1) JP7792730B2 (enExample)
CN (1) CN116715633B (enExample)
TW (1) TWI870839B (enExample)
WO (1) WO2023208108A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119241538A (zh) * 2024-09-30 2025-01-03 陕西科技大学 一类三唑并吡啶结构的化合物、合成方法及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044403A1 (ja) 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 ５員環ヘテロアリール誘導体及びその医薬用途
WO2014157740A1 (ja) 2013-03-29 2014-10-02 帝人ファーマ株式会社 ピラゾール誘導体
WO2016121777A1 (ja) 2015-01-28 2016-08-04 アステラス製薬株式会社 ピラジンカルボキサミド化合物の製造方法及びその合成中間体
WO2017038723A1 (ja) 2015-08-28 2017-03-09 Ils株式会社 キサンチンオキシダーゼ阻害剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050090529A1 (en) * 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
MX2008001778A (es) * 2005-08-19 2008-04-07 Aventis Pharma Inc Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
CA2623327A1 (en) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
WO2010044404A1 (ja) * 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 縮合複素環誘導体及びその医薬用途
WO2010093191A2 (en) * 2009-02-13 2010-08-19 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
JP5990106B2 (ja) * 2011-01-28 2016-09-07 佐藤製薬株式会社 縮環化合物
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
HUE052608T2 (hu) * 2015-09-02 2021-05-28 Sunshine Lake Pharma Co Ltd Karboxi-szubsztituált (hetero) aromás gyûrûs származékok, elõállítási eljárásaik és alkalmazásaik
EA037280B1 (ru) * 2015-09-10 2021-03-03 Цзянсу Атом Байосайенс Энд Фармасьютикал Ко., Лтд. Группа соединений, применяющихся для лечения или предупреждения гиперурикемии или подагры
CN107759588B (zh) * 2016-08-19 2020-10-23 江苏新元素医药科技有限公司 一类苯基-(吡唑并[1,5-a]吡啶-3-基)甲酮衍生物
BR112021001709A2 (pt) * 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
CN116438175B (zh) * 2020-11-11 2025-07-22 南京明德新药研发有限公司 苯并脲环衍生物及其制备方法和应用
WO2022233264A1 (zh) * 2021-05-07 2022-11-10 江苏新元素医药科技有限公司 一类黄嘌呤氧化酶抑制剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010044403A1 (ja) 2008-10-15 2010-04-22 キッセイ薬品工業株式会社 ５員環ヘテロアリール誘導体及びその医薬用途
WO2014157740A1 (ja) 2013-03-29 2014-10-02 帝人ファーマ株式会社 ピラゾール誘導体
WO2016121777A1 (ja) 2015-01-28 2016-08-04 アステラス製薬株式会社 ピラジンカルボキサミド化合物の製造方法及びその合成中間体
WO2017038723A1 (ja) 2015-08-28 2017-03-09 Ils株式会社 キサンチンオキシダーゼ阻害剤

Also Published As

Publication number Publication date
TW202342456A (zh) 2023-11-01
CN116715633B (zh) 2025-08-12
EP4516781A1 (en) 2025-03-05
US20250282753A1 (en) 2025-09-11
TWI870839B (zh) 2025-01-21
JP2025514336A (ja) 2025-05-02
WO2023208108A1 (zh) 2023-11-02
EP4516781A4 (en) 2026-04-29
CN116715633A (zh) 2023-09-08

Similar Documents

Publication Publication Date Title
RU2730500C2 (ru) Производное хиназолинона, способ его получения, фармацевтическая композиция и применения
JP7713253B2 (ja) キサンチンオキシダーゼ抑制剤
JP7798362B2 (ja) Ｂｃｌ－２阻害剤としての化合物
JP2025513483A (ja) ピラゾール置換シクロペンチルエステル誘導体及びその用途
ES3059451T3 (en) Compound used as ret kinase inhibitor and application thereof
CN119790055A (zh) 吡唑并嘧啶化合物及其医药用途
WO2020043173A1 (zh) 作为受体相互作用蛋白1(rip1)激酶抑制剂的杂环化合物
WO2015008229A1 (en) Autotaxin inhibitors
JP2022549496A (ja) Ｃｒｆ受容体アンタゴニストおよび使用方法
CN120731207A (zh) 6-烷氧基吡唑并嘧啶化合物及其药学用途
JP2025514336A (ja) 尿酸を降下させるために使用できる化合物
CN115974855B (zh) Ezh2和hdac双靶点抑制剂、其药物组合物及其制备方法和用途
JP2025514336A5 (enExample)
AU2023292912A1 (en) Prodrugs of stat3 inhibitors
KR20150079677A (ko) 디아실글리세롤 아실트랜스퍼라제 억제제로서의 신규 화합물
CN111662239B (zh) 1,2,4-三唑类化合物及其制法和药物用途
WO2025098445A1 (zh) Parg抑制剂及其制备方法和用途
WO2024235218A1 (zh) Hdac1/2选择性抑制剂及其用途
CN116836154B (zh) 可用于痛风的化合物
WO2023010078A9 (en) Muscarinic receptor 4 antagonists and methods of use
RU2823875C1 (ru) Гетероциклическое амидное соединение, его фармацевтически приемлемая соль, способ его получения и применение
JP2024537383A (ja) ボロン酸誘導体
TW201831177A (zh) 醯胺衍生物
WO2024140653A1 (zh) 选择性cdk12/13抑制剂及其应用
WO2025185643A1 (zh) 用作cdk4蛋白激酶抑制剂的化合物及其应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251209

R150 Certificate of patent or registration of utility model

Ref document number: 7792730

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150